All Updates

All Updates

icon
Filter
Partnerships
Product updates
Insilico Medicine delivers second preclinical candidate compound to Fosun Pharma
AI Drug Discovery
Jul 5, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
AI Drug Discovery

AI Drug Discovery

Jul 5, 2024

Insilico Medicine delivers second preclinical candidate compound to Fosun Pharma

Partnerships
Product updates

  • AI-powered drug developer Insilico Medicine has completed the second preclinical candidate compound (PCC) in collaboration with Fosun Pharma. This compound is potentially a new therapeutic for treating solid tumors using a synthetic lethal strategy. The companies expect to submit the candidate for pre-IND application by Q4 2024.

  • The compound targets DNA damage repair mechanisms, a significant aspect of tumor therapy. The process leveraged Insilico’s PandaOmics, an AI target identification engine, and Life Star 1, an AI-operated lab. Chemistry42, another AI tool, created compounds expressly for the target. The compound is claimed to have shown promising results in preclinical studies, with anti-tumor efficacy and impressive ADMET properties. Fosun Pharma plans to take on the compound for further research and development after Insilico advances it to the IND-enabling stage.

  • Analyst QuickTake : The partnership between Insilico Medicine and Fosun Pharma was established in January 2022 . It was aimed to develop multiple drug targets, including Insilico’s Glutaminyl-peptide cyclotransferase-like (QPCTL) program, and to develop Fosun’s internal drug development programs using Insilico's PandaOmics and Chemistry42 platforms.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.